KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in IntangiblesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Astrazeneca (AZN) over the last 15 years, with Q4 2025 value amounting to -$1.0 billion.

  • Astrazeneca's Capital Expenditures fell 4632.77% to -$1.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$2.8 billion, marking a year-over-year decrease of 4604.99%. This contributed to the annual value of -$2.8 billion for FY2025, which is 4604.99% down from last year.
  • As of Q4 2025, Astrazeneca's Capital Expenditures stood at -$1.0 billion, which was down 4632.77% from -$686.0 million recorded in Q3 2025.
  • Astrazeneca's Capital Expenditures' 5-year high stood at $1.9 billion during Q4 2021, with a 5-year trough of -$1.0 billion in Q4 2025.
  • In the last 5 years, Astrazeneca's Capital Expenditures had a median value of -$335.0 million in 2021 and averaged -$289.5 million.
  • As far as peak fluctuations go, Astrazeneca's Capital Expenditures soared by 1924.31% in 2021, and later crashed by 7251.31% in 2025.
  • Quarter analysis of 5 years shows Astrazeneca's Capital Expenditures stood at $1.9 billion in 2021, then plummeted by 113.61% to -$253.0 million in 2022, then decreased by 6.72% to -$270.0 million in 2023, then plummeted by 162.22% to -$708.0 million in 2024, then plummeted by 46.33% to -$1.0 billion in 2025.
  • Its Capital Expenditures was -$1.0 billion in Q4 2025, compared to -$686.0 million in Q3 2025 and -$659.0 million in Q2 2025.